Viridian Therapeutics, Inc. - Common Stock (VRDN)

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Viridian Therapeutics (VRDN) exemplifies the Minervini SEPA strategy, combining a strong technical uptrend with explosive fundamental sales and earnings growth momentum.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

The results are also promising for the next-generation version of that drug.

Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans to submit an FDA application for veligrotug in 2025.